A Review on Modern Treatment Approach-Nanogel Against Bacterial Conjuctivitis
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901230224146432 |
|---|---|
| author | Manoj S.*1, Dr. Beny Baby1, Dr. S. Rajarajan2, Akhilesh Kumar Yadav1 |
| author_facet | Manoj S.*1, Dr. Beny Baby1, Dr. S. Rajarajan2, Akhilesh Kumar Yadav1 |
| contents | <p><span lang="EN-IN">A common eye condition called bacterial conjunctivitis can be brought on by two prevalent pathogens: Staphylococcus aureus and Streptococcus pneumoniae. Conventional antibiotic treatments are becoming less effective as the prevalence of resistance among these bacterial types rises. This study investigates the etiology of bacterial conjunctivitis as well as the clinical manifestations and symptoms of affected individuals. Due to corneal epithelial impermeability and precorneal loss, current ocular medication administration techniques frequently have insufficient bioavailability. These drawbacks are extensively discussed. Nanogel technology holds promise as a solution to these problems, providing better drug delivery. Nanogels exploit their unique physiochemical properties to allow the controlled and extended release of therapeutic chemicals, therefore addressing challenges of rapid drug clearance and insufficient penetration into target tissues. This study describes a variety of methods for creating nanogels, including ionic gelation, emulsion solvent diffusion, nanoprecipitation, and emulsion evaporation, and highlights how they might improve the outcomes of therapy for eye conditions. This work demonstrates how nanogel systems is have the effective treatment of bacterial conjunctivitis by combining innovative formulation techniques, delivery methods, and knowledge of medication resistance. </span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_15191424 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | A Review on Modern Treatment Approach-Nanogel Against Bacterial Conjuctivitis Manoj S.*1, Dr. Beny Baby1, Dr. S. Rajarajan2, Akhilesh Kumar Yadav1 Nanogels, Ocular Drug Delivery, Bacterial Conjunctivitis, Drug Bioavailability, Therapeutic Efficacy, Controlled Release, Antibacterial Resistance <p><span lang="EN-IN">A common eye condition called bacterial conjunctivitis can be brought on by two prevalent pathogens: Staphylococcus aureus and Streptococcus pneumoniae. Conventional antibiotic treatments are becoming less effective as the prevalence of resistance among these bacterial types rises. This study investigates the etiology of bacterial conjunctivitis as well as the clinical manifestations and symptoms of affected individuals. Due to corneal epithelial impermeability and precorneal loss, current ocular medication administration techniques frequently have insufficient bioavailability. These drawbacks are extensively discussed. Nanogel technology holds promise as a solution to these problems, providing better drug delivery. Nanogels exploit their unique physiochemical properties to allow the controlled and extended release of therapeutic chemicals, therefore addressing challenges of rapid drug clearance and insufficient penetration into target tissues. This study describes a variety of methods for creating nanogels, including ionic gelation, emulsion solvent diffusion, nanoprecipitation, and emulsion evaporation, and highlights how they might improve the outcomes of therapy for eye conditions. This work demonstrates how nanogel systems is have the effective treatment of bacterial conjunctivitis by combining innovative formulation techniques, delivery methods, and knowledge of medication resistance. </span></p> |
| title | A Review on Modern Treatment Approach-Nanogel Against Bacterial Conjuctivitis |
| topic | Nanogels, Ocular Drug Delivery, Bacterial Conjunctivitis, Drug Bioavailability, Therapeutic Efficacy, Controlled Release, Antibacterial Resistance |
| url | https://doi.org/10.5281/zenodo.15191424 |